Oncogene: CRIPTO和它的信号伴侣GRP78能促使人类前列腺癌骨转移表型

2017-04-16 AlexYang MedSci原创

CRIPTO (CR-1,TDGF1)是一个细胞表面/分泌的肿瘤蛋白并积极的参与发育和癌症。最近,研究人员报道了CRIPTO的高表达与前列腺癌(PCa)患者分层风险组的低生存率有关。研究结果发现,CRIPTO和它的信号伴侣-葡萄糖调节的蛋白78(GRP78)在PCa转移肿瘤中高度表达,并且与非转移性ALDHlow比较,在PC-3M-Pro4Luc2 PCa 细胞的转移性ALDHhigh亚群中有着更

CRIPTO (CR-1,TDGF1)是一个细胞表面/分泌的肿瘤蛋白并积极的参与发育和癌症。最近,研究人员报道了CRIPTO的高表达与前列腺癌(PCa)患者分层风险组的低生存率有关。

研究结果发现,CRIPTO和它的信号伴侣-葡萄糖调节的蛋白78(GRP78)在PCa转移肿瘤中高度表达,并且与非转移性ALDHlow比较,在PC-3M-Pro4Luc2 PCa 细胞的转移性ALDHhigh亚群中有着更高的表达。研究人员将骨转移PC-3M-Pro4Luc2 PCa 细胞与分化的人类初级造骨细胞共培养后诱导了CRIPTO和GRP78在癌细胞中的表达,并且增加了ALDHhigh亚群的规模。另外,CRIPTO或GRP78的敲除减少了细胞增殖、迁移、集落形成和ALDHhigh亚群的规模。研究人员还发现,CRIPTO敲除可以减少斑马鱼中PC-3M-Pro4Luc2细胞的侵入性,并且可以抑制前临床小鼠模型的骨转移。最后,研究人员指出,这些结果强调了CRIPTO和GRP78在PCa转移中的功能角色,并且指出了将CRIPTO/GRP78信号作为靶标也许有着明显的治疗潜力。

原始出处:

E Zoni, L Chen, S Karkampouna et al. CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer. Oncogene. 10 April 2017. doi: 10.1038/onc.2017.87.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048812, encodeId=2e0420488125d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Nov 21 20:53:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189721, encodeId=374e189e2135, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 22 23:25:44 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535128, encodeId=a1561535128a4, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558066, encodeId=fdcc1558066fa, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615846, encodeId=2aa8161584655, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-11-21 仁心济世
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048812, encodeId=2e0420488125d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Nov 21 20:53:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189721, encodeId=374e189e2135, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 22 23:25:44 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535128, encodeId=a1561535128a4, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558066, encodeId=fdcc1558066fa, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615846, encodeId=2aa8161584655, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-22 虈亣靌

    感谢分享一下!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2048812, encodeId=2e0420488125d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Nov 21 20:53:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189721, encodeId=374e189e2135, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 22 23:25:44 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535128, encodeId=a1561535128a4, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558066, encodeId=fdcc1558066fa, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615846, encodeId=2aa8161584655, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048812, encodeId=2e0420488125d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Nov 21 20:53:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189721, encodeId=374e189e2135, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 22 23:25:44 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535128, encodeId=a1561535128a4, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558066, encodeId=fdcc1558066fa, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615846, encodeId=2aa8161584655, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=)]
    2017-04-18 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048812, encodeId=2e0420488125d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Nov 21 20:53:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189721, encodeId=374e189e2135, content=感谢分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Apr 22 23:25:44 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535128, encodeId=a1561535128a4, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558066, encodeId=fdcc1558066fa, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615846, encodeId=2aa8161584655, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Tue Apr 18 02:53:00 CST 2017, time=2017-04-18, status=1, ipAttribution=)]

相关资讯

J UROLOGY:二甲双胍不能增加前列腺癌的生存期

根据4月份The Journal of Urology发表的一项研究表明,二甲双胍与多西他赛联合使用并不能显着改善糖尿病伴转移性去势抵抗性前列腺癌患者的生存期。

Sci Rep:对高胰岛素血症可嫁接免疫缺陷小鼠模型的一些研究看法

高胰岛素血症、肥胖和血脂异常是许多癌症独立、聚合风险因素。最近,研究人员调查了适用于人体组织异体种植的两个免疫缺陷小鼠株系((NOD/SCID 和 Rag1-/-)中,23%西方高脂肪饮食(HFD)的长期影响,以及饮食诱导的高胰岛素血症对人类前列腺癌细胞系异种种植生长的影响。研究人员发现,断奶16周和23周后,Rag1-/- 和 NOD/SCID HFD喂养的小鼠表现出了在葡萄糖耐受性中饮食诱导的

Prostate Cancer P D:一个基于国家癌症数据库的回顾分析:2004年到2013年前列腺癌IIA阶段放射疗法运用趋势情况

最近的研究展现了在过去几十年中,放射疗法治疗前列腺癌的方法利用正在减少,更加保守的全面治疗方法同样存在减少趋势。最近,有研究人员对在2004年到2013年,这种减少的趋势是否持续以及各种不同放射疗法的利用的变化情况进行了研究。研究人员利用国家癌症数据库资料进行了一项回顾性研究。研究鉴定了在2003到2013年具有充足治疗信息并且被诊断为前列腺癌IIA阶段的706877名病人,并运用逻辑回归模型去评

Nat Commun:能够引起前列腺癌中microRNAs异常代谢的拮抗转录驱使因子的鉴定

雄激素阻断疗法是治疗转移性前列腺癌的标准疗法,但是,总会导致出现抗性现象。因此,对另外一些驱使因子的系统鉴定也许可以对有效疗法的开发提供有用的信息。很多的microRNAs对代谢具有很重要的作用,但在转移性前列腺癌症中却被异常调节了。然而,潜在的分子机制却知之甚少。最近,研究人员对转录因子(TF)和microRNAs的表达谱做了一个整体的分析,并计算鉴定了三个主效TFs,AR、HOXC6和NKX2

PROSTATE CANCER P D:前列腺癌常见治疗手段与痴呆存在关联性

前列腺癌的雄激素剥夺疗法是较为常用的肿瘤治疗手段,其常见的不良反应为骨质疏松和骨折风险。而最新的研究表明,雄激素剥夺疗法与男性前列腺癌患者痴呆的发生存在某些相关性,可能的原因是雄激素对于神经元的维护作用受到影响,与阿尔茨海默病尚无定论,有待进一步研究。一项新的分析研究显示接受雄性激素剥夺疗法(ADT)治疗的前列腺癌患者与痴呆存在关联性,雄性激素剥夺疗法是一种雄激素降低治疗手段。该研究来自于宾夕法尼

Sci Rep:MAOA,一个新的激素抵抗性神经内分泌前列腺癌细胞凋亡和自我吞噬的决定者

自我吞噬和细胞凋亡是两个精细的控制机制来调控细胞的命运。但是,人们对细胞命运走向决定因子的理解还在初期。单胺氧化酶A(MAOA)是一个线粒体酶,且在精神病研究中被人熟知。越来越多的报道表明了MAOA的超表达与前列腺癌(PCa)有关。最近,研究人员展示了MAOA参与了PCa细胞神经内分泌分化的调控,并且该细胞为激素抵抗性PCa(HRPC),是一种致死的疾病类型。接着,最近的报道展示了PCa的神经内分